Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs ZPL 3893787 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Ziarco
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 24 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
- 24 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2016.